Capitalbio Tech Announced the Closure of CNY 800 Mn Pre-IPO Funding
CapitalBio Tech, a Beijing-based molecular diagnostics product and service provider, today announced that it completed a pre-IPO funding round of over CNY 800 million.
The investment is led by Guangdong Boye Architectural Design Institute (backed by Country Garden), participated by China Petrochemical Corporation, Meinian OneHealth, New Alliance Capital and other investors.
CapitalBio plans to utilize this bankroll to accelerate the R&D process of new products, expand chip pipelines, further deploying business portfolio in medical fertility, infection, oncology. Meanwhile it also eye on building up its sales team and market promotion to explore overseas business. Part of this capital injection will be used for a future IPO registration on the SSE Star Market.
Associated Companies: Meinian Onehealth